Cefoxitin
JFDA label: Foxitin IV/IM
Mechanism of Action
Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.
Indications
Approved
- Bone and joint infections
- Gynecological infections
- Intra-abdominal infections
- Lower respiratory tract infections
- Perioperative prophylaxis
- Septicemia
- Skin and skin structure infections
- Urinary tract infections
Off-label
- Bite wounds (animal)
Antimicrobial Spectrum
Expected / intrinsic spectrum (EUCAST breakpoints & labels) — not local resistance. Source: openfda-label.
Bacteria
| Organism | Activity | MIC |
|---|---|---|
| Bacteroides fragilis | Active | — |
| Chlamydia trachomatis | Active | — |
| Clostridium perfringen | Active | — |
| Enterococcus faecalis | Active | — |
| Escherichia coli | Active | — |
| Haemophilus influenzae | Active | — |
| Morganella morganii | Active | — |
| Neisseria gonorrhoeae | Active | — |
| Prevotella bivia | Active | — |
| Proteus mirabilis | Active | — |
| Proteus vulgaris | Active | — |
| Staphylococcus aureus | Active | — |
| Staphylococcus epidermidis | Active | — |
| Streptococcus agalactiae | Active | — |
| Streptococcus faecalis | Active | — |
| Streptococcus pneumoniae | Active | — |
| Streptococcus pyogenes | Active | — |
Class profile
| gramStatus | Both |
|---|---|
| spectrumBreadth | Moderate |
| atypicalCoverage | No |
| isBactericidal | 1 |
| moaCategory | Cell wall synthesis inhibitor (beta-lactam, 2nd generation cephamycin) |
| pdIndex | Time-dependent |
| postAntibioticEffect | None |
| mrsaCoverage | 0 |
| resistanceMechanisms | AmpC beta-lactamase,PBP mutations |
Contraindications
Source: Lexicomp
- Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins Absolute
Adverse Reactions
Other (1)
Common Gastrointestinal: Diarrhea
Dosing
Source: Lexicomp
Warnings & Precautions
Source: Lexicomp
Hypersensitivity
Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria). If a hypersensitivity reaction occurs, discontinue immediately.
Superinfection
Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Disease-related concerns:
GI disease
Use with caution in patients with a history of gastrointestinal disease, particularly colitis.
Renal impairment
Use with caution in patients with renal impairment; modify dosage in severe impairment.
Seizure disorders
Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures. Special populations:
Children
In pediatric patients ≥3 months of age, higher doses have been associated with an increased incidence of eosinophilia and elevated AST.
Elderly
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function; use care in dose selection and monitor renal function. Other warnings/precautions:
Discontinuation of therapy
For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis.
Pregnancy & Lactation
Pregnancy
Adverse events have not been observed in animal reproduction studies. Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid. Peak serum concentrations of cefoxitin during pregnancy may be similar to or decreased compared to nonpregnant values. Maternal half-life may be shorter at term. Pregnancy-induced hypertension increases trough concentrations in the immediate postpartum period. Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.
Lactation
Very small amounts of cefoxitin are excreted in breast milk. The manufacturer recommends that caution be exercised when administering cefoxitin to nursing women. Nondose-related effects could include modification of bowel flora. Cefoxitin pharmacokinetics may be altered immediately postpartum.
Monitoring
| Efficacy | Culture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin) |
|---|---|
| Toxicity | Renal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea) |
| Clinical pearl | Culture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship). |
| Counseling | Complete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h. |
Chemistry & Properties
| Formula | C16H17N3O7S2 |
|---|---|
| Molecular weight | 427.46 g/mol |
| IUPAC name | (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| CAS | 35607-66-0 |
| PubChem CID | 441199 |
| InChIKey | WZOZEZRFJCJXNZ-ZBFHGGJFSA-N |
| logP | 0.1 (XLogP 0.0) |
| Polar surface area | 148.26 Ų |
| H-bond acceptors / donors | 8 / 3 |
| Drug-likeness (QED) | 0.41 |
| Lipinski violations | 0 |
SMILES
CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@@H]21Biology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|---|
| Half-life | 0.879 h |
| Volume of distribution | 0.196 L/kg |
| Protein binding | 44.7% |
| BBB penetrant | No |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OAT3 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)PEPT1 (Inhibitor)P-gp (Substrate)PEPT1 (Substrate)
Drug–drug interactions (14, DDInter)
| Interacting drug | Severity | Management |
|---|---|---|
| Amikacin | moderate | |
| Amikacin (liposome) | moderate | |
| Chloramphenicol | moderate | |
| Dicoumarol | moderate | |
| Ethinylestradiol | moderate | |
| Gentamicin | moderate | |
| Kanamycin | moderate | |
| Mycophenolic acid | moderate | |
| Neomycin | moderate | |
| Pemetrexed | moderate | |
| Picosulfuric acid | moderate | |
| Streptomycin | moderate | |
| Warfarin | moderate | |
| Heparin | minor |
Registered Products (1)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Foxitin IV/IM | Vial 1 g | 1 vial | Sukhtian Group | 5.730 |